Skip to content

Andrew Biggerstaff

3 papers in the library · 45 citations · publishing 2017-2020

Papers

Sort Most recent Most cited

Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain

Frontiers in Neuroscience July 21, 2020 Kelly F Paton, Andrew Biggerstaff, Sophia Kaska et al.

In the search for safer, non-addictive analgesics, kappa opioid receptor (KOPr) agonists are a potential target, as unlike mu-opioid analgesics, they do not have abuse potential. Salvinorin A (SalA) is a potent and selective KOPr agonist, however, clinical utility is limited by the short duration of action and aversive side effects. Biasing KOPr signaling toward G-protein activation has been...

Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents.

Molecules October 11, 2018 Bronwyn M Kivell, Kelly F Paton, Nitin Kumar et al. 45 citations

The acute activation of kappa opioid receptors (KOPr) produces antinociceptive and anti-cocaine effects, however, their side-effects have limited further clinical development. Mesyl Sal B is a potent and selective KOPr analogue of Salvinorin A (Sal A), a psychoactive natural product isolated from the plant Salvia divinorum. We assessed the antinociceptive, anti-cocaine, and side-effects of...

Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.

Journal of Medicinal Chemistry May 11, 2017 Alexander M. Sherwood, Rachel Saylor Crowley, Kelly F Paton et al.

Previous structure-activity studies on the neoclerodane diterpenoid salvinorin A have demonstrated the importance of the acetoxy functionality on the A-ring in its activity as a κ-opioid receptor agonist. Few studies have focused on understanding the role of conformation in these interactions. Herein we describe the synthesis and evaluation of both flexible and conformationally restricted...